United States securities and exchange commission logo October 22, 2020 Kate DeVarney President Titan Pharmaceuticals, Inc. 400 Oyster Point Boulevard, Suite 505 South San Francisco, California 94080 Re: Titan Pharmaceuticals, Inc. Registration Statement on Form S-1 Filed October 19, 2020 File No. 333-249550 Dear Ms. DeVarney: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Courtney Lindsay at (202) 551-7237 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences